-
Seminars in Hematology Jan 1991
Review
Topics: Antithrombin III; Antithrombin III Deficiency; Humans; Thromboembolism
PubMed: 2017685
DOI: No ID Found -
Clinical Science (London, England :... May 2017The gene encodes a serine protease inhibitor named antithrombin III (ATIII). This protease demonstrates both anticoagulant and anti-inflammatory action. ATIII is the... (Review)
Review
The gene encodes a serine protease inhibitor named antithrombin III (ATIII). This protease demonstrates both anticoagulant and anti-inflammatory action. ATIII is the most important coagulation factor inhibitor, and even minor changes in ATIII can significantly alter the risk of thromboembolism. ATIII can also suppress inflammation via a coagulation-dependent or -independent effect. Moreover, apart from ATIII deficiency, ATIII and its gene may also be related to many diseases (e.g. hypertension, kidney diseases). The present review summarizes how ATIII affects the progress of kidney disease and its mechanism. Further studies are required to investigate how ATIII affects renal function and the treatment.
Topics: Antithrombin III; Antithrombin III Deficiency; Blood Coagulation; Humans; Inflammation; Kidney Diseases; Models, Biological; Risk Factors; Signal Transduction; Thromboembolism
PubMed: 28424376
DOI: 10.1042/CS20160669 -
Intensive Care Medicine Jul 1998
Review
Topics: Antithrombin III; Disseminated Intravascular Coagulation; Humans; Sepsis
PubMed: 9722032
DOI: 10.1007/s001340050639 -
Danish Medical Bulletin Mar 1983
Review
Topics: Adolescent; Adult; Aged; Antithrombin III; Antithrombin III Deficiency; Blood Coagulation Disorders; Female; Heparin; Humans; Infant, Newborn; Male; Middle Aged; Pregnancy; Thromboembolism
PubMed: 6342984
DOI: No ID Found -
Thrombosis and Haemostasis Mar 1995Treatment with AT III concentrates is a good example for the discrepancy between the optimistic expectations based on theoretical considerations or animal experiments... (Review)
Review
Treatment with AT III concentrates is a good example for the discrepancy between the optimistic expectations based on theoretical considerations or animal experiments and the result of clinical studies. 15 years after the introduction into clinical practice, a benefit for patients treated with AT III concentrates has not been proven. In hereditary antithrombin III deficiency, randomized clinical trials are completely lacking and only few and small sized randomized studies were performed in patients with acquired AT III deficiency. In none of these trials, a significant clinical benefit with regard to reduction of morbidity or mortality was detectable. Based on the published data, one can state that AT III concentrates may be beneficial in some special clinical situations in patients with hereditary antithrombin III deficiency (such as delivery, acute serious thromboembolic complications and postoperative thromboprophylaxis). In acquired AT III deficiency, there is no proven indication for the use of AT III concentrates.
Topics: Antithrombin III; Antithrombin III Deficiency; Asparaginase; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Infant, Newborn; Kidney Diseases; Liver Diseases; Postoperative Complications; Pregnancy; Pregnancy Complications, Hematologic; Randomized Controlled Trials as Topic; Safety; Shock, Septic; Thromboembolism
PubMed: 7667814
DOI: No ID Found -
Minerva Anestesiologica May 2002Antithrombin III plays many different roles during cardiac operations with cardiopulmonary bypass. Basically, it acts as the natural inhibitor of thrombin, which, in... (Review)
Review
Antithrombin III plays many different roles during cardiac operations with cardiopulmonary bypass. Basically, it acts as the natural inhibitor of thrombin, which, in presence of heparin, blocks the thrombin action and avoids gross thrombus formation inside the extracorporeal circulation circuit. By acting as a "suicide substrate", antithrombin III is consumed during cardiopulmonary bypass; at the same time, thrombin is extensively formed during and after cardiopulmonary bypass. As a result, at the end of the operation there is a potential imbalance in the antithrombin III-thrombin interaction, leading to a prothrombotic status. Moreover, patients pre-treated with heparin reach the operating theater with reduced levels of circulating antithrombin III; this may lead to the heparin resistance phenomenon and may further increase the risk for postoperative thrombotic complications. Finally, the anti-inflammatory properties of antithrombin III in the setting of the "whole body inflammatory reaction" induced by the cardiopulmonary bypass represents a new and unexplored field of research.
Topics: Anticoagulants; Antithrombin III; Cardiopulmonary Bypass; Extracorporeal Circulation; Heparin; Humans; Inflammation; Serine Proteinase Inhibitors; Thrombosis
PubMed: 12029263
DOI: No ID Found -
Clinics in Haematology Jun 1981
Review
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Female; Humans; Male; Nephrotic Syndrome; Risk; Thrombophlebitis
PubMed: 7032781
DOI: No ID Found -
Hematology/oncology Clinics of North... Oct 1992The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III... (Review)
Review
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired AT III deficiency are reported.
Topics: Antithrombin III; Antithrombin III Deficiency; Chromatography, Affinity; Humans; Thrombosis; Virus Diseases
PubMed: 1400075
DOI: No ID Found -
Zhonghua Fu Chan Ke Za Zhi May 1988
Review
Topics: Antithrombin III; Antithrombin III Deficiency; Disseminated Intravascular Coagulation; Heparin; Humans
PubMed: 3058418
DOI: No ID Found -
Problemy Gematologii I Perelivaniia... Mar 1982
Review
Topics: Antithrombin III; Blood Coagulation; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Liver Cirrhosis; Male; Pulmonary Embolism
PubMed: 7045862
DOI: No ID Found